Spruce Biosciences (SPRB) Net Equity Issued and Repurchased (2020)
Spruce Biosciences (SPRB) posted quarterly Net Equity Issued and Repurchased of $44.0 million for Q3 2020, up 628457.14% quarter-over-quarter from -$7000.0 in Q2 2020.
Spruce Biosciences (SPRB) Net Equity Issued and Repurchased (2020) Analysis & Trends
Spruce Biosciences (SPRB) has reported Net Equity Issued and Repurchased for 1 consecutive years, with $44.0 million the latest figure, recorded in Q3 2020.
- In Q3 2020, Net Equity Issued and Repurchased changed N/A year-over-year to $44.0 million; the TTM figure through Dec 2020 stood at $87.6 million (changed N/A YoY), while the FY2020 annual figure was $87.6 million, up 1003.55% from the prior year.
- Net Equity Issued and Repurchased improved to $44.0 million in Q3 2020 per SPRB's latest filing, from -$7000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $44.0 million in Q3 2020 and bottomed at -$7000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 43.99 Mn |
| Sep 30, 2020 | 43.99 Mn |
| Jun 30, 2020 | -7,000.00 |
| Jun 30, 2020 | -7,000.00 |
| Mar 31, 2020 | 43.66 Mn |
| Mar 31, 2020 | 43.66 Mn |